Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Extension Study of FYU-981 in Hyperuricemic Pediatric Patients With or Without Gout
jRCT2041220061Phase 3Completed
- Sponsor
- Fuji Yakuhin
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dotinurad in hyperuricemia and gout, sponsored by Fuji Yakuhin. Primary endpoint: Serum urate response at end of administration. Started Jan 2023; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on jRCT2041220061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220061.